The Therapeutic Goods Administration (TGA), with the support of the NSW, Victorian and Queensland state governments, commissioned a team to review the available scientific evidence for the use of cannabis medicines in five areas: palliative care, nausea and vomiting, epilepsy, multiple sclerosis and pain.
The NSW Government supported the review to provide a source of credible information about the available evidence to support medical practitioners considering prescribing a cannabis medicine for their patient.
The guidance developed for medical practitioners is available on the TGA's website and includes:
- an overview of cannabis medicines
- guidance in relation to epilepsy
- guidance in relation to multiple sclerosis
- guidance in relation to nausea and vomiting
- guidance in relation to palliative care
- guidance in relation to chronic non-cancer pain
The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), based at the University of Newcastle, received funding from the NSW Government to develop practical NSW Cannabis Medicines Prescribing Guidance.
Prescribing Guidance documents have been developed to provide information to support NSW medical practitioners in prescribing cannabis medicines to patients for conditions where cannabinoids are perceived to have some benefit. They are available on ACRE’s website.
- Clinical trials
- Talking to your patient
- Prescribing pathways
- Information and support for prescribers
- Clinical guidelines
- Children and vulnerable people
Residential aged cared facilities